VALVOLINE INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VALVOLINE INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $594.00M | Nov 21, 2018 |
| FY2018 | Jun 30, 2018 | $577.00M | Nov 21, 2018 |
| FY2018 | Mar 31, 2018 | $569.00M | Nov 21, 2018 |
| FY2018 | Dec 31, 2017 | $545.00M | Nov 21, 2018 |
| FY2018 | Sep 30, 2017 | $547.00M | Nov 21, 2018 |
| FY2018 | Jun 30, 2017 | $534.00M | Nov 21, 2018 |
| FY2018 | Mar 31, 2017 | $514.00M | Nov 21, 2018 |
| FY2018 | Dec 31, 2016 | $489.00M | Nov 21, 2018 |
| FY2017 | Sep 30, 2016 | $494.00M | Nov 17, 2017 |
| FY2017 | Jun 30, 2016 | $499.00M | Nov 17, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.71B | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $1.62B | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | $1.44B | Nov 21, 2025 |
| FY2022 | Sep 30, 2022 | $335.40M | Dec 2, 2022 |
| FY2022 | Jun 30, 2022 | $317.40M | Dec 2, 2022 |
| FY2022 | Mar 31, 2022 | $296.00M | Dec 2, 2022 |
| FY2022 | Dec 31, 2021 | $287.30M | Dec 2, 2022 |
| FY2022 | Sep 30, 2021 | $295.20M | Dec 2, 2022 |
| FY2022 | Jun 30, 2021 | $281.60M | Dec 2, 2022 |
| FY2022 | Mar 31, 2021 | $244.90M | Dec 2, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $658.50M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $618.80M | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | $544.50M | Nov 21, 2025 |
| FY2022 | Sep 30, 2022 | $129.10M | Dec 2, 2022 |
| FY2022 | Jun 30, 2022 | $127.80M | Dec 2, 2022 |
| FY2022 | Mar 31, 2022 | $107.30M | Dec 2, 2022 |
| FY2022 | Dec 31, 2021 | $112.20M | Dec 2, 2022 |
| FY2022 | Sep 30, 2021 | $119.40M | Dec 2, 2022 |
| FY2022 | Jun 30, 2021 | $126.00M | Dec 2, 2022 |
| FY2022 | Mar 31, 2021 | $105.50M | Dec 2, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $210.70M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $211.50M | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | $1.42B | Nov 21, 2025 |
| FY2022 | Sep 30, 2022 | $157.70M | Dec 2, 2022 |
| FY2022 | Jun 30, 2022 | $98.20M | Dec 2, 2022 |
| FY2022 | Mar 31, 2022 | $81.40M | Dec 2, 2022 |
| FY2022 | Dec 31, 2021 | $87.00M | Dec 2, 2022 |
| FY2022 | Sep 30, 2021 | $168.90M | Dec 2, 2022 |
| FY2022 | Jun 30, 2021 | $96.90M | Dec 2, 2022 |
| FY2022 | Mar 31, 2021 | $67.80M | Dec 2, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $389.90M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $367.20M | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | $247.20M | Nov 21, 2025 |
| FY2022 | Sep 30, 2022 | $67.20M | Dec 2, 2022 |
| FY2022 | Jun 30, 2022 | $61.10M | Dec 2, 2022 |
| FY2022 | Mar 31, 2022 | $40.00M | Dec 2, 2022 |
| FY2022 | Dec 31, 2021 | $52.00M | Dec 2, 2022 |
| FY2022 | Sep 30, 2021 | $87.70M | Dec 2, 2022 |
| FY2022 | Jun 30, 2021 | $69.30M | Dec 2, 2022 |
| FY2022 | Mar 31, 2021 | $51.20M | Dec 2, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $15.00M | Nov 19, 2021 |
| FY2021 | Sep 30, 2020 | $13.00M | Nov 19, 2021 |
| FY2021 | Sep 30, 2019 | $13.00M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $14.00M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $13.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $13.00M | Nov 21, 2018 |
| FY2017 | Sep 30, 2015 | $11.00M | Nov 17, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $349.90M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $305.10M | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | $264.50M | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $244.70M | Nov 22, 2024 |
| FY2023 | Sep 30, 2021 | $223.90M | Nov 20, 2023 |
| FY2022 | Sep 30, 2020 | $177.20M | Dec 2, 2022 |
| FY2021 | Sep 30, 2019 | $449.00M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $430.00M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $396.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $365.00M | Nov 21, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $297.20M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $265.10M | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | ($40.80M) | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $284.20M | Nov 22, 2024 |
| FY2023 | Sep 30, 2021 | $403.90M | Nov 20, 2023 |
| FY2022 | Sep 30, 2020 | $371.70M | Dec 2, 2022 |
| FY2021 | Sep 30, 2019 | $325.00M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $320.00M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | ($130.00M) | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $311.00M | Nov 21, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $259.20M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $224.40M | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | $180.50M | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $132.00M | Nov 22, 2024 |
| FY2023 | Sep 30, 2021 | $103.10M | Nov 20, 2023 |
| FY2022 | Sep 30, 2020 | $94.00M | Dec 2, 2022 |
| FY2021 | Sep 30, 2019 | $108.00M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $93.00M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $68.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $66.00M | Nov 21, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.67B | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $2.44B | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $2.89B | Nov 22, 2024 |
| FY2023 | Sep 30, 2022 | $3.42B | Nov 20, 2023 |
| FY2022 | Sep 30, 2021 | $3.19B | Dec 2, 2022 |
| FY2021 | Sep 30, 2020 | $3.05B | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | $2.06B | Nov 24, 2020 |
| FY2019 | Sep 30, 2018 | $1.85B | Nov 22, 2019 |
| FY2018 | Sep 30, 2017 | $1.92B | Nov 21, 2018 |
| FY2017 | Sep 30, 2016 | $1.83B | Nov 17, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $338.50M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $185.60M | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | $203.20M | Nov 21, 2025 |
| FY2025 | Sep 30, 2022 | $306.60M | Nov 21, 2025 |
| FY2024 | Sep 30, 2021 | $134.50M | Nov 22, 2024 |
| FY2023 | Sep 30, 2020 | ($76.00M) | Nov 20, 2023 |
| FY2022 | Sep 30, 2019 | ($257.80M) | Dec 2, 2022 |
| FY2021 | Sep 30, 2018 | ($358.00M) | Nov 19, 2021 |
| FY2020 | Sep 30, 2017 | ($117.00M) | Nov 24, 2020 |
| FY2019 | Sep 30, 2016 | ($330.00M) | Nov 22, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $658.00M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $615.30M | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | $578.00M | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $548.20M | Nov 22, 2024 |
| FY2023 | Sep 30, 2021 | $512.80M | Nov 20, 2023 |
| FY2022 | Sep 30, 2020 | $316.10M | Dec 2, 2022 |
| FY2021 | Sep 30, 2019 | $430.00M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $381.00M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $330.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $264.00M | Nov 21, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $273.60M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $123.20M | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $140.70M | Nov 22, 2024 |
| FY2023 | Sep 30, 2022 | $282.00M | Nov 20, 2023 |
| FY2022 | Sep 30, 2021 | $90.00M | Dec 2, 2022 |
| FY2021 | Sep 30, 2020 | ($110.00M) | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | ($284.00M) | Nov 24, 2020 |
| FY2019 | Oct 1, 2018 | ($412.00M) | Nov 22, 2019 |
| FY2019 | Sep 30, 2018 | ($399.00M) | Nov 22, 2019 |
| FY2018 | Sep 30, 2017 | ($167.00M) | Nov 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $51.60M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | $68.30M | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | $409.10M | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $23.40M | Nov 22, 2024 |
| FY2023 | Sep 30, 2021 | $122.60M | Nov 20, 2023 |
| FY2022 | Sep 30, 2020 | $639.70M | Dec 2, 2022 |
| FY2021 | Sep 30, 2019 | $159.00M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $96.00M | Nov 24, 2020 |
| FY2018 | Sep 30, 2017 | $201.00M | Nov 21, 2018 |
| FY2018 | Sep 30, 2016 | $172.00M | Nov 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 1 | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | 1 | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | 8 | Nov 21, 2025 |
| FY2022 | Sep 30, 2022 | 0 | Dec 2, 2022 |
| FY2022 | Jun 30, 2022 | 0 | Dec 2, 2022 |
| FY2022 | Mar 31, 2022 | 0 | Dec 2, 2022 |
| FY2022 | Dec 31, 2021 | 0 | Dec 2, 2022 |
| FY2022 | Sep 30, 2021 | 0 | Dec 2, 2022 |
| FY2022 | Jun 30, 2021 | 0 | Dec 2, 2022 |
| FY2022 | Mar 31, 2021 | 0 | Dec 2, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 1 | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | 1 | Nov 21, 2025 |
| FY2025 | Sep 30, 2023 | 8 | Nov 21, 2025 |
| FY2022 | Sep 30, 2022 | 0 | Dec 2, 2022 |
| FY2022 | Jun 30, 2022 | 0 | Dec 2, 2022 |
| FY2022 | Mar 31, 2022 | 0 | Dec 2, 2022 |
| FY2022 | Dec 31, 2021 | 0 | Dec 2, 2022 |
| FY2022 | Sep 30, 2021 | 0 | Dec 2, 2022 |
| FY2022 | Jun 30, 2021 | 0 | Dec 2, 2022 |
| FY2022 | Mar 31, 2021 | 0 | Dec 2, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 127.10M | Nov 21, 2025 |
| FY2025 | Sep 30, 2024 | 128.50M | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | 134.80M | Nov 22, 2024 |
| FY2023 | Sep 30, 2022 | 176.10M | Nov 20, 2023 |
| FY2022 | Sep 30, 2021 | 180.30M | Dec 2, 2022 |
| FY2021 | Sep 30, 2020 | 185.00M | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | 188.00M | Nov 24, 2020 |
| FY2019 | Sep 30, 2018 | 188.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2017 | 203.00M | Nov 21, 2018 |
| FY2017 | Sep 30, 2016 | 205.00M | Nov 17, 2017 |